Background: Irritable bowel syndrome (IBS) reduces quality of life and burdens healthcare systems. This study identified factors associated with frequent use of IBS diagnostic tests and procedures. Methods: Using a United States claims database (2001-2012), tests and procedures in IBS patients occurring in the 2-year study period (12 months before/following the first IBS diagnosis) were analyzed: endoscopy, GI transit testing, anorectal procedures, and radiologic imaging. Patients were classified based on test/procedure frequency (3+, 1-2, or 0). Multivariate logistic regression identified factors associated with more frequent tests/ procedures. Results: Among 201,322 IBS patients, 41.7% had 3+ tests/procedures, 35.1% had 1-2, and 23.3% had 0. Patients with more tests/procedures were older [mean age 50.6 (3+ group), more likely to be female and had more comorbidities, including anxiety, depressive disorders, and somatization. Dyspepsia [odds ratio (95% confidence interval): 1.80 (1.72-1.87)], interstitial cystitis [1.60 (1.45-1.77)], gastroesophageal reflux disease [1.59 (1.55-1.63)], constipation [1.50 (1.45-1.54)], and dyspareunia [1. 38 (1.25-1.52) ] were significantly associated with more tests/ procedures (3+ versus 1-2), while anxiety, depressive disorders, and somatization were not. Patients with more frequent specialist visits [emergency department (ED; 1.10 (1.09-1.11)) and gastroenterologists (1.26 (1.26-1.27))] or at least one GI-related ED visit or inpatient admission [1.95 (1.86-2.04) and 3.67 (3.48-3.87), respectively] were more likely to have more tests/ procedures (all p < 0.05). Conclusions: Test frequency in patients with IBS is strongly associated with demographic and clinical characteristics, especially comorbid conditions related to IBS. Presence of common overlapping comorbid conditions should increase clinicians' confidence in making the diagnosis of IBS, thus curtailing redundant testing and reducing healthcare costs.
Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder that affects 10-15% of the United States (US) population, 1 with a higher prevalence among women and patients under 50 years of age. 2 IBS is characterized by recurrent abdominal pain and altered bowel habits; bloating and distension frequently coexist. Symptoms are frequently chronic, which can negatively impact patients' quality of life. 3, 4 Diagnosing IBS can be challenging due to the nonspecific nature of symptoms, overlapping upper and lower abdominal symptoms, and the frequent presence of somatic and psychological comorbidities. 3 The Rome IV guidelines state that diagnostic tests may be appropriate in the evaluation of a patient with IBS symptoms. 5 However, no validated algorithm for diagnostic tests exists. The Rome criteria are most often used during IBS diagnosis, and clinical guidelines on the management of IBS have been developed to help improve and standardize treatment. [6] [7] [8] Despite these guidelines, there remains low awareness and little consensus on the use of diagnostic tests and surgical procedures in IBS. 9, 10 Furthermore, although surgery has no role in the recommended treatment approach for IBS, 8 multiple studies have reported that this patient population is predisposed to unnecessary surgical procedures, [11] [12] [13] [14] suggesting a disconnect between the recommended best practices and real-world management of IBS.
IBS causes a significant burden on healthcare systems, due in part to the high level of healthcare resource utilization (HRU) associated with IBS. 15 Direct medical costs attributed to IBS in the US, excluding prescription and over-the-counter medicines, were estimated at US $1.5-$10 billion per year in 2005. 16 A portion of these costs may be related to unnecessary 17 and high-frequency tests, 14 although few studies have assessed the factors underlying frequent tests and procedures among patients with IBS. A claims study (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) ) reported large regional variation in levels of HRU among patients with IBS in the US; 15 however, the reasons for the differences are unclear. A systematic review and meta-analysis found that certain comorbidities, such as depression and anxiety, are prevalent among this patient population, which may contribute to higher HRU including tests and procedures. 18 However, prior studies have not adequately evaluated the demographic and clinical factors which influence the use, and overuse, of diagnostic tests and procedures among IBS patients.
This study assessed the demographic and clinical factors associated with high test frequency among adults with IBS in the US. We hypothesized that patients with more comorbid conditions overlapping with IBS, or psychological disorders such as anxiety, depression, or somatization, would be likely to undergo relatively frequent tests/diagnostic procedures.
Methods

Data source
Data were derived from the Truven Health Analytics MarketScan ® databases (1 January 2001 to 31 December 2012, the latest period with US state-level data), a large retrospective US commercial claims database that is nationally representative of Americans with employer-provided health insurance and Medicaid. 19 The database contains information regarding patient demographics, health plan enrollment history, medical diagnoses, procedures performed, dates and places of service, and payment amounts as well as prescription drug claims for over 25 million covered lives annually.
Patient selection and groups
Patients were included in the study if they (1) had at least two separate and distinct diagnoses for IBS [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code 564.1x] recorded on different dates between 1 January 2001 and 31 December 2012; (2) had ⩾12 months of continuous healthcare plan enrollment before and after the first recorded IBS diagnosis; and (3) were aged ⩾18 years on the date of the first recorded IBS diagnosis, with no upper age limit.
Patients were categorized into three groups based on the frequency of tests/procedures received during the 2-year study period: the high-count group (⩾3 tests/procedures), the moderate-count group (1-2 tests/procedures), and the zero-count group (0 tests/procedures). Tests were summarized by category level (i.e. colonoscopy, anoscopy, Sitzmark test) and patients were permitted to have the same procedure once per day; the same test on different days or multiple tests with separate codes on the same day were considered to be separate procedures. Appendix A contains a list of included GI tests/procedures along with their corresponding diagnostic and procedural codes used to search the claims database. Physician specialty was recorded, identified based on a corresponding annotation in the data.
This study was not subject to review by an Institutional Review Board, and no informed consent was needed, as ethics approval was not required for this national database study.
Study period and measures
The study period was defined as the 2-year period surrounding the first recorded IBS diagnosis (i.e. 1 year before and on/after the first IBS diagnosis date). The index date was defined as the date of the first recorded IBS diagnosis. Data collected during the study period included patient demographics, including age at IBS diagnosis, sex, region of residence, and insurance plan type; clinical characteristics, including modified Charlson-Quan comorbidity index (CCI; a composite measure of patient's health) 20 and IBS-related comorbidities [e.g. dyspepsia, gastroesophageal reflux disease (GERD), interstitial cystitis, anxiety, depressive disorders, and somatization; see Appendix B; note that constipation, while clinically considered an IBS symptom, had to be computed as a comorbidity, as at the time of the study there was no specific coding for IBS with constipation]; and HRU, including all-cause medical visits stratified by provider type (e.g. family practice, internal medicine, emergency medicine), intestinal-related emergency department (ED) visits, and inpatient admissions. IBS medical procedures and tests were identified in the database using ICD-9-CM and Current Procedural Terminology (CPT) codes (see Appendix A). Types of healthcare plans included preferred provider organization (PPO), health maintenance organization (HMO), comprehensive coverage (i.e. total coverage for healthcare-related charges), point of service (POS)/POS with capitation, consumer-directed health plan (CDHP)/highdeductible health plan (HDHP), exclusive provider organization (EPO), and 'unknown.'
Statistical analysis
Pairwise comparisons of patient demographic and clinical characteristics were conducted across the high-, moderate-, and low-count groups using Chi-squared tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. Univariate and multivariate logistic regression models, comparing the high-and moderate-count groups, were estimated to identify factors associated with more frequent use of tests/procedures. The multivariate regression models used stepwise selection to choose the most relevant variables while generating a parsimonious model. Results were reported as an odds ratio (OR) and corresponding 95% confidence interval (CI). The proportions of patients with different combinations of comorbid conditions were summarized for the zero-, moderate-, and high-count groups. A p value of 0.05 was used to determine statistical significance.
Results
Demographic and clinical characteristics of patients with IBS
A total of 201,322 IBS patients met the inclusion criteria ( Figure 1 ), with 83,852 (42%), 70,577 (35%), and 46,892 (23%) patients in the high-, moderate-, and zero-count test groups, respectively ( Figure 2 ). Across all groups, patients were predominantly from the south (40.5-43.5%, including the following US states: Alabama, North Carolina, South Carolina, Georgia, Texas, Mississippi, Louisiana, Florida) and had PPO insurance (57.0-59.0%; Table 1 ).
Patients in the high-count group were older (50.6 years) and there was a larger proportion of females (79.5%) compared with the moderatecount (49.5 years and 76.7%, respectively) and zero-count (46.8 years and 74.0%) groups (all p < 0.0001; Table 1 ). The high-count group also had a higher CCI [mean 2.2 versus 1.4 (moderate-count) and 1.1 (zero-count); all p < 0.0001] and the highest prevalence of all observed IBSrelated comorbidities. Pronounced trends of higher rates of comorbidity associated with higher numbers of tests were observed for dyspepsia (high-count: 13.0%, moderate-count: 5.8%, zero-count: 2.6%; all p < 0.0001), GERD (40.4%, 24.0%, and 15.2%, respectively; all p < 0.0001), constipation (25.6%, 15%, and 7.8%; all p < 0.0001), and depressive disorders (23.5%, 17.7%, and 17.5%; p < 0.0001 for high-count versus zero-count and moderate-count). Anxiety was significantly more prevalent in the high-count group (20.4%) compared with the moderate-or zero-count groups (15.5%, and 15.8%; both p < 0.0001 versus high-count). Somatization was significantly more prevalent among patients in the high-count group (0.2%) compared with the moderate-count and zero-count group (both 0.1%; both p < 0.0001 versus high-count).
Patient HRU and costs related to IBS. The highcount group had significantly higher mean numbers of annual medical visits to all provider types compared with the moderate-count and zerocount groups, as follows: family practice: 6.5, 4.5, and 3.9, respectively; internal medicine: Patients in the high-count group had ⩾3 tests/procedures in the 2-year study period, those in the moderate-count group had 1-2 tests/procedures, and those in the zero-count group had no tests/procedures. IBS diagnosis was identified by a claim with ICD-9 code 564.1x. IBS, irritable bowel syndrome; ICD, International Classification of Diseases, ninth revision; N, number. In addition, the proportions of the high-count, moderate-count, and zero-count groups with two of these four comorbidities were as follows: dyspareunia and dyspepsia (overall n = 295; 76.6%, 21.0%, and 2.4%, respectively); dyspareunia and GERD (936; 68.7%, 24.8%, and 6.5%); dyspareunia and interstitial cystitis (186; 73.7%, 21.5%, 10.2%); dyspepsia and GERD (8214; 73.7%, 21.8%, and 4.5%); dyspepsia and interstitial cystitis (257; 82.9%, 14.0%, and 3.1%); and GERD and interstitial cystitis (946; 74.8%, 18.9%, and 6.2%; Table 3 ). When including patients with three or all of these comorbidities, the proportions were even more greatly skewed towards the highversus the moderate-count or zero-count groups: dyspareunia, dyspepsia, and GERD (overall n = 169; 81.1%, 17.8%, and 1.2%, respectively); dyspareunia, dyspepsia, and interstitial cystitis (30; 90.0%, 10.0%, and 0%); dyspareunia, GERD, and interstitial cystitis (74; 73%, 17.6%, and 9.5%); dyspepsia, GERD, and interstitial cystitis (150; 88.7%, 9.3%, and 2.0%); and dyspareunia, dyspepsia, GERD, and interstitial cystitis (20; 90.0%, 10.0%, and 0%; Table 3 and Figure 3 ).
Discussion
IBS is a common, chronic and complex GI disorder associated with a significant burden to the healthcare system. The negative financial impact of IBS is related, in part, to the large number of diagnostic tests and procedures performed on IBS patients despite the lack of evidence supporting their need or clinical utility. In this retrospective claims database study of 201,322 patients with IBS, we found that most (41.7%) patients had at least IBS-related diagnostic tests/procedures. After assessing factors associated with frequent use of IBS-related diagnostics tests/procedures, we observed that test/procedure frequency was significantly associated with older age, female sex, GI-related ED or inpatient visits, high overall comorbidity burden, and certain individual comorbidities (GERD, dyspepsia, interstitial cystitis, constipation, and dyspareunia).
Our findings also suggest that the overall health of patients in the high-count group was generally worse than in the others (higher mean CCI) and thus may provide a rationale for the increased number of tests/procedures. Similar to prior studies, we found high comorbidity burden in this population of patients with IBS, particularly anxiety, depressive disorders, and somatization, 14, 18, 21 although these comorbidities were not associated with a higher test frequency. This is important clinically, as it suggests that coexisting anxiety and depression are not driving factors in ordering tests or procedures. In the multivariable analysis, the two comorbidities most strongly associated with a high test frequency were dyspepsia and interstitial cystitis. Dyspepsia and interstitial cystitis are notable in that they involve subjective feelings of abdominal pain, arise from multiple and diverse etiologies, and are often interrelated. 22, 23 Abdominal pain is a primary predictor of increased HRU among patients with IBS, 4 and quality of life is highly associated with patient-perceived IBS severity. 24 Our results suggest that abdominal pain arising from multiple overlapping upper and lower abdominal causes (e.g. dyspepsia and IBS and dyspareunia) is a driving factor in providers ordering tests and procedures. The picture that emerges from our study, taken together with prior observations, is one in which functional bowel disorders often present together, 25 leading to diagnostic testing approaches that become additive in burden, but not necessarily in benefit.
The current findings have implications for patients, care providers, and payers. Given the lack of consensus on the therapeutic value and clinical utility of tests and procedures in the diagnosis and treatment of IBS, our study indicates that many patients with IBS are subjected to diagnostic tests and procedures which are neither required nor essential or beneficial. 6 Unfortunately, this strategy is expensive to both patients and payers, 26 and carries significant risks, including adverse events during these procedures. The large proportion of patients receiving multiple tests/procedures over the study period provides strong evidence for the need to increase awareness of physician practice guidelines for the diagnosis and treatment of IBS. 9, 10 Common practices for IBS management begin with diet and lifestyle modification, and in more severe cases, pharmacotherapy (e.g. antidepressants, smooth muscle antispasmodics, or secretagogues). 27 However, in the real world, several studies have noted the high utilization of surgical procedures, related or unrelated to IBS, among patients with IBS. [11] [12] [13] [14] For example, an analysis of the medical records (1995-2000) of a large cohort of patients with IBS showed that the incidence of abdominopelvic surgery (excluding gallbladder) was 87% higher among these patients versus control patients. 13 At least one inpatient admission or ED visit was a highly significant risk factor for ⩾3 versus 1-2 tests/procedures among this study sample. Prior studies have consistently found that patients with IBS undergo frequent hospitalizations, which appears to be a driver of increased test frequency. For example, a prior survey of HMO participants with IBS found that, over 2 years, these patients had significantly more outpatient and inpatient visits, as well as more ED visits, compared with patients without IBS. 26 Similarly, a large managed-care cohort study reported that patients with IBS were more likely than control patients to have blood, stool, endoscopic, and radiologic tests, and to undergo abdominal/pelvic surgery. 14 Higher rates of HRU together with higher frequencies of tests (which may be related to inpatient admissions and frequent provider visits) may compound the cost of IBS treatment. The reasons behind the higher HRU among patients with IBS are not well known. Patients with IBS and high levels of somatization are not more likely to seek out GI tests/procedures; however, once they are evaluated for IBS, they expend significantly more healthcare costs compared with matched controls. 28 Region of residence has also been reported to impact HRU among IBS patients. A claims database study of HRU in patients with IBS (2001-2012) identified considerable regional variation across the US and noted that 36.3% of patients had ⩾3 different types of GI medical tests/procedures in the a 2-year period surrounding IBS diagnosis. 15 In summary, care providers for patients with IBS face a complex decision landscape, where an interplay of underlying patient characteristics, possibly including aspects of their psyche and behaviors, such as their tendency (or not) to seek frequent medical attention, may compound the challenges posed by the presentation of IBS symptoms that frequently overlap with a number of IBS-related comorbidities (Figure 4 ). In the midst of these factors, healthcare professionals have to make cost-effective decisions about appropriate diagnostic tests and interventions, creating a fertile ground that may foster over-testing and redundant procedures.
Future prospective studies could help gain a better understanding of the reasons why diagnostic tests are ordered and evaluate the clinical utility of these tests/procedures regarding the diagnosis and treatment of IBS. This information should strengthen clinical practice guidelines and potentially reduce the economic burden of IBS on the healthcare system. In addition, future studies could expand upon the current analysis by stratifying outcomes by IBS subtype, which could not be performed in this study, as separate ICD-9 codes for IBS subtypes did not exist at the time of data collection.
This study is subject to several limitations. Overall, our study only included patients with IBS and did not provide a matched comparison with a non-IBS reference population. Prior studies have already shown high HRU rates specific to IBS, 14, 25 and this is a premise that we did not further investigate in our study in the context of diagnostic tests. While we believe that our observations suggest that these patients often undergo excessive testing and are diagnosed by exclusion, an approach inconsistent with the current Rome IV criteria, 5 it is true that our study does not close this particular question. A matched comparison to quantify the volume of diagnostic tests with negative results in this population relative to non-IBS individuals would go a long way to more definitively answer the question of whether the excess in diagnostic testing that we observe in IBS patients is truly unwarranted. Given the substantial economic impact of IBS 16, 29 (a combination of productivity losses, increased interventions and, according to our study, diagnostic procedures), this becomes a pressing question to follow up. There are also specific limitations. First, as with any claims data analysis, this analysis relied on ICD-9-CM and CPT codes to identify diagnoses and procedures within the database, as opposed to actual observance of diagnoses and resource use. However, patients required two separate diagnoses of IBS, which minimizes the possibility of coding errors; in addition, as a byproduct of following the coding system, constipation, which is clinically an IBS symptom (for the disease subtype IBS-C), had to be counted as a comorbidity because IBS subtypes were not coded as such. Second, this study was based on a population of commercially-insured beneficiaries in the US, and the generalizability to other patient populations (e.g. Medicaid, which would include mostly low-income patients younger than 65 years) is unknown. In addition, a large proportion of the included patients were from the southern US (40.5-43.5%), which may limit the representativeness of the sample; race or ethnicity was not included as a variable in the analysis. Third, the results of this study should be interpreted as correlations which may not have causal interpretations. For instance, because tests and hospitalizations were assessed over the same study period, the findings do not imply that hospitalizations or emergency room (ER) visits are associated with future tests that are not directly related to the hospitalization/ER visit; indeed, the association may be mainly due to tests during the hospitalization or ER visit. Or, in another example, we document that patients with higher test counts tend to be older or have higher CCI; it is possible that at least some of those 'excess' tests could be directly driven by those factors, more so than the IBS diagnosis. However, many of the concurrent comorbidities specific to the highcount group were IBS-related and associated with abdominal pain symptoms, an observation that strongly suggests the underlying IBS pathology was an important (and redundant) trigger for a substantial proportion of those tests. Therefore, considering our findings and our study limitations, we are not proposing that clinicians radically curtail diagnostic tests in patients presenting with multiple functional bowel and abdominal symptoms, particularly in elderly patients. We would favor an approach in which clinicians are proactively judicious, weighing all the factors present in a given patient as they decide a diagnostic strategy for them, rather than reacting narrowly to individual symptoms.
Conclusion
This study provides real-world evidence that the frequency of IBS-related diagnostic tests/procedures is strongly associated with a patient's demographic and clinical profile, especially their comorbidity profile. In the clinical setting, healthcare providers equipped with the knowledge that overlapping comorbid conditions of GERD, dyspepsia, and dyspareunia are not just common in IBS patients, but likely explain many of the symptoms reported by IBS patients, should enable clinicians to minimize redundant diagnostic tests and procedures and instead focus on initiating individualized treatment. This should reduce healthcare costs globally and improve patients' quality of life.
